Lung Cancer Diagnostics Market Size, Trends, Analysis, and Outlook By Product (Instruments, Consumables & Accessories), By Test (Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Others), By End-user (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Others), By Distribution Channel (Direct Tender, Retail Sales), by Region, Country, Segment, and Companies, 2024-2030
The global Lung Cancer Diagnostics market size is poised to register 8.93% growth from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Lung Cancer Diagnostics market across By Product (Instruments, Consumables & Accessories), By Test (Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Others), By End-user (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Others), By Distribution Channel (Direct Tender, Retail Sales).
The Lung Cancer Diagnostics market is experiencing substantial growth attributed to the increasing incidence of lung cancer worldwide, growing adoption of early screening programs, and advancements in diagnostic technologies. Lung cancer diagnostics encompass a range of tests and procedures aimed at detecting, staging, and monitoring lung tumors, enabling timely intervention and personalized treatment strategies. Factors such as the rising prevalence of risk factors such as smoking, air pollution, and occupational exposures, and the need for effective screening tools for high-risk populations are driving market expansion. Additionally, the development of non-invasive imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) for lung cancer detection and staging, and the emergence of liquid biopsy and molecular testing for tumor biomarker analysis and treatment selection are fueling innovation in the market. Moreover, the increasing emphasis on multi-disciplinary approaches to lung cancer management, integration of artificial intelligence (AI) and machine learning algorithms for image interpretation and risk stratification, and efforts to improve access to diagnostics in underserved regions are driving market growth. Furthermore, collaborations between diagnostic companies, research institutions, and healthcare providers to develop novel biomarkers and technologies, and initiatives to raise awareness about lung cancer screening and early detection are expected to further propel market growth in the coming years.
Lung Cancer Diagnostics Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Lung Cancer Diagnostics market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Lung Cancer Diagnostics survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Lung Cancer Diagnostics industry.
Key market trends defining the global Lung Cancer Diagnostics demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
Lung Cancer Diagnostics Market Segmentation- Industry Share, Market Size, and Outlook to 2030
The Lung Cancer Diagnostics industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Lung Cancer Diagnostics companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the Lung Cancer Diagnostics industry
Leading Lung Cancer Diagnostics companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Lung Cancer Diagnostics companies.
Lung Cancer Diagnostics Market Study- Strategic Analysis Review
The Lung Cancer Diagnostics market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
The Lung Cancer Diagnostics industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.
Lung Cancer Diagnostics Country Analysis and Revenue Outlook to 2030
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.
North America Lung Cancer Diagnostics Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Lung Cancer Diagnostics market segments. Similarly, Strong end-user demand is encouraging Canadian Lung Cancer Diagnostics companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Lung Cancer Diagnostics market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe Lung Cancer Diagnostics Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Lung Cancer Diagnostics industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Lung Cancer Diagnostics market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific Lung Cancer Diagnostics Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Lung Cancer Diagnostics in Asia Pacific. In particular, China, India, and South East Asian Lung Cancer Diagnostics markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.
Latin America Lung Cancer Diagnostics Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa Lung Cancer Diagnostics Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Lung Cancer Diagnostics market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Lung Cancer Diagnostics.
Lung Cancer Diagnostics Market Company Profiles
The global Lung Cancer Diagnostics market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are 20/20 Gene Systems, Abbott, Amoy Diagnostics Co. Ltd, Biocartis, Biodesix, Bio-Rad Laboratories Inc, Boditech Med Inc, Danaher, DiaSorin S.p.A., Exact Sciences UK Ltd, F. Hoffmann-La Roche Ltd., Guardant Health Inc, Inivata Ltd., LalPathLabs.com, LungLife AI Inc, MedGenome, Myriad Genetics Inc, Nanoentek, NanoString, NeoGenomics Laboratories, Oncocyte Corp, PerkinElmer Inc, PlexBio, QIAGEN, Quest Diagnostics Inc, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc, Vela Diagnostics, Veracyte Inc
Recent Lung Cancer Diagnostics Market Developments
The global Lung Cancer Diagnostics market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
Lung Cancer Diagnostics Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
By Product
Instruments
Consumables & Accessories
By Test
Biomarkers Tests
Imaging Test
Biopsy
Blood Test
Others
By End-User
Hospital
Associated Labs
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Others
By Distribution Channel
Direct Tender
Retail Sales
Geographical Segmentation:
20/20 Gene Systems
Abbott
Amoy Diagnostics Co. Ltd
Biocartis
Biodesix
Bio-Rad Laboratories Inc
Boditech Med Inc
Danaher
DiaSorin S.p.A.
Exact Sciences UK Ltd
F. Hoffmann-La Roche Ltd.
Guardant Health Inc
Inivata Ltd.
LalPathLabs.com
LungLife AI Inc
MedGenome
Myriad Genetics Inc
Nanoentek
NanoString
NeoGenomics Laboratories
Oncocyte Corp
PerkinElmer Inc
PlexBio
QIAGEN
Quest Diagnostics Inc
Siemens Healthcare GmbH
Thermo Fisher Scientific Inc
Vela Diagnostics
Veracyte Inc
Formats Available: Excel, PDF, and PPT
The Lung Cancer Diagnostics market is experiencing substantial growth attributed to the increasing incidence of lung cancer worldwide, growing adoption of early screening programs, and advancements in diagnostic technologies. Lung cancer diagnostics encompass a range of tests and procedures aimed at detecting, staging, and monitoring lung tumors, enabling timely intervention and personalized treatment strategies. Factors such as the rising prevalence of risk factors such as smoking, air pollution, and occupational exposures, and the need for effective screening tools for high-risk populations are driving market expansion. Additionally, the development of non-invasive imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) for lung cancer detection and staging, and the emergence of liquid biopsy and molecular testing for tumor biomarker analysis and treatment selection are fueling innovation in the market. Moreover, the increasing emphasis on multi-disciplinary approaches to lung cancer management, integration of artificial intelligence (AI) and machine learning algorithms for image interpretation and risk stratification, and efforts to improve access to diagnostics in underserved regions are driving market growth. Furthermore, collaborations between diagnostic companies, research institutions, and healthcare providers to develop novel biomarkers and technologies, and initiatives to raise awareness about lung cancer screening and early detection are expected to further propel market growth in the coming years.
Lung Cancer Diagnostics Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Lung Cancer Diagnostics market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Lung Cancer Diagnostics survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Lung Cancer Diagnostics industry.
Key market trends defining the global Lung Cancer Diagnostics demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
Lung Cancer Diagnostics Market Segmentation- Industry Share, Market Size, and Outlook to 2030
The Lung Cancer Diagnostics industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Lung Cancer Diagnostics companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the Lung Cancer Diagnostics industry
Leading Lung Cancer Diagnostics companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Lung Cancer Diagnostics companies.
Lung Cancer Diagnostics Market Study- Strategic Analysis Review
The Lung Cancer Diagnostics market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
- Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.
- Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.
- Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.
- Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.
The Lung Cancer Diagnostics industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.
Lung Cancer Diagnostics Country Analysis and Revenue Outlook to 2030
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.
North America Lung Cancer Diagnostics Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Lung Cancer Diagnostics market segments. Similarly, Strong end-user demand is encouraging Canadian Lung Cancer Diagnostics companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Lung Cancer Diagnostics market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe Lung Cancer Diagnostics Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Lung Cancer Diagnostics industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Lung Cancer Diagnostics market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific Lung Cancer Diagnostics Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Lung Cancer Diagnostics in Asia Pacific. In particular, China, India, and South East Asian Lung Cancer Diagnostics markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.
Latin America Lung Cancer Diagnostics Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa Lung Cancer Diagnostics Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Lung Cancer Diagnostics market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Lung Cancer Diagnostics.
Lung Cancer Diagnostics Market Company Profiles
The global Lung Cancer Diagnostics market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are 20/20 Gene Systems, Abbott, Amoy Diagnostics Co. Ltd, Biocartis, Biodesix, Bio-Rad Laboratories Inc, Boditech Med Inc, Danaher, DiaSorin S.p.A., Exact Sciences UK Ltd, F. Hoffmann-La Roche Ltd., Guardant Health Inc, Inivata Ltd., LalPathLabs.com, LungLife AI Inc, MedGenome, Myriad Genetics Inc, Nanoentek, NanoString, NeoGenomics Laboratories, Oncocyte Corp, PerkinElmer Inc, PlexBio, QIAGEN, Quest Diagnostics Inc, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc, Vela Diagnostics, Veracyte Inc
Recent Lung Cancer Diagnostics Market Developments
The global Lung Cancer Diagnostics market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
Lung Cancer Diagnostics Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
- Pricing Analysis
- Value Chain Analysis
- SWOT Profile
- Market Dynamics- Trends, Drivers, Challenges
- Porter’s Five Forces Analysis
- Macroeconomic Impact Analysis
- Case Scenarios- Low, Base, High
By Product
Instruments
Consumables & Accessories
By Test
Biomarkers Tests
Imaging Test
Biopsy
Blood Test
Others
By End-User
Hospital
Associated Labs
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Others
By Distribution Channel
Direct Tender
Retail Sales
Geographical Segmentation:
- North America (3 markets)
- Europe (6 markets)
- Asia Pacific (6 markets)
- Latin America (3 markets)
- Middle East Africa (5 markets)
20/20 Gene Systems
Abbott
Amoy Diagnostics Co. Ltd
Biocartis
Biodesix
Bio-Rad Laboratories Inc
Boditech Med Inc
Danaher
DiaSorin S.p.A.
Exact Sciences UK Ltd
F. Hoffmann-La Roche Ltd.
Guardant Health Inc
Inivata Ltd.
LalPathLabs.com
LungLife AI Inc
MedGenome
Myriad Genetics Inc
Nanoentek
NanoString
NeoGenomics Laboratories
Oncocyte Corp
PerkinElmer Inc
PlexBio
QIAGEN
Quest Diagnostics Inc
Siemens Healthcare GmbH
Thermo Fisher Scientific Inc
Vela Diagnostics
Veracyte Inc
Formats Available: Excel, PDF, and PPT
1. EXECUTIVE SUMMARY
1.1 Lung Cancer Diagnostics Market Overview and Key Findings, 2024
1.2 Lung Cancer Diagnostics Market Size and Growth Outlook, 2021- 2030
1.3 Lung Cancer Diagnostics Market Growth Opportunities to 2030
1.4 Key Lung Cancer Diagnostics Market Trends and Challenges
1.4.1 Lung Cancer Diagnostics Market Drivers and Trends
1.4.2 Lung Cancer Diagnostics Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Lung Cancer Diagnostics Companies
2. LUNG CANCER DIAGNOSTICS MARKET SIZE OUTLOOK TO 2030
2.1 Lung Cancer Diagnostics Market Size Outlook, USD Million, 2021- 2030
2.2 Lung Cancer Diagnostics Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. LUNG CANCER DIAGNOSTICS MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. LUNG CANCER DIAGNOSTICS MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Product
Instruments
Consumables & Accessories
By Test
Biomarkers Tests
Imaging Test
Biopsy
Blood Test
Others
By End-User
Hospital
Associated Labs
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Others
By Distribution Channel
Direct Tender
Retail Sales
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific Lung Cancer Diagnostics Market, 2025
5.2 Asia Pacific Lung Cancer Diagnostics Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Lung Cancer Diagnostics Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Lung Cancer Diagnostics Market, 2025
5.5 Europe Lung Cancer Diagnostics Market Size Outlook by Type, 2021- 2030
5.6 Europe Lung Cancer Diagnostics Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Lung Cancer Diagnostics Market, 2025
5.8 North America Lung Cancer Diagnostics Market Size Outlook by Type, 2021- 2030
5.9 North America Lung Cancer Diagnostics Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Lung Cancer Diagnostics Market, 2025
5.11 South America Pacific Lung Cancer Diagnostics Market Size Outlook by Type, 2021- 2030
5.12 South America Lung Cancer Diagnostics Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Lung Cancer Diagnostics Market, 2025
5.14 Middle East Africa Lung Cancer Diagnostics Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Lung Cancer Diagnostics Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US Lung Cancer Diagnostics Market Size Outlook and Revenue Growth Forecasts
6.2 US Lung Cancer Diagnostics Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Lung Cancer Diagnostics Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Lung Cancer Diagnostics Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Lung Cancer Diagnostics Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Lung Cancer Diagnostics Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Lung Cancer Diagnostics Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Lung Cancer Diagnostics Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Lung Cancer Diagnostics Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Lung Cancer Diagnostics Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Lung Cancer Diagnostics Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Lung Cancer Diagnostics Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Lung Cancer Diagnostics Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Lung Cancer Diagnostics Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Lung Cancer Diagnostics Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Lung Cancer Diagnostics Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Lung Cancer Diagnostics Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Lung Cancer Diagnostics Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Lung Cancer Diagnostics Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Lung Cancer Diagnostics Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Lung Cancer Diagnostics Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Lung Cancer Diagnostics Industry Drivers and Opportunities
7. LUNG CANCER DIAGNOSTICS MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. LUNG CANCER DIAGNOSTICS COMPANY PROFILES
8.1 Profiles of Leading Lung Cancer Diagnostics Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
20/20 GENE SYSTEMS
Abbott
Amoy Diagnostics Co. Ltd
Biocartis
Biodesix
Bio-Rad Laboratories Inc
Boditech Med Inc
Danaher
DiaSorin S.p.A.
Exact Sciences UK Ltd
F. Hoffmann-La Roche Ltd.
Guardant Health Inc
Inivata Ltd.
LalPathLabs.com
LungLife AI Inc
MedGenome
Myriad Genetics Inc
Nanoentek
NanoString
NeoGenomics Laboratories
Oncocyte Corp
PerkinElmer Inc
PlexBio
QIAGEN
Quest Diagnostics Inc
Siemens Healthcare GmbH
Thermo Fisher Scientific Inc
Vela Diagnostics
Veracyte Inc
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
1.1 Lung Cancer Diagnostics Market Overview and Key Findings, 2024
1.2 Lung Cancer Diagnostics Market Size and Growth Outlook, 2021- 2030
1.3 Lung Cancer Diagnostics Market Growth Opportunities to 2030
1.4 Key Lung Cancer Diagnostics Market Trends and Challenges
1.4.1 Lung Cancer Diagnostics Market Drivers and Trends
1.4.2 Lung Cancer Diagnostics Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Lung Cancer Diagnostics Companies
2. LUNG CANCER DIAGNOSTICS MARKET SIZE OUTLOOK TO 2030
2.1 Lung Cancer Diagnostics Market Size Outlook, USD Million, 2021- 2030
2.2 Lung Cancer Diagnostics Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. LUNG CANCER DIAGNOSTICS MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. LUNG CANCER DIAGNOSTICS MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Product
Instruments
Consumables & Accessories
By Test
Biomarkers Tests
Imaging Test
Biopsy
Blood Test
Others
By End-User
Hospital
Associated Labs
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Others
By Distribution Channel
Direct Tender
Retail Sales
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific Lung Cancer Diagnostics Market, 2025
5.2 Asia Pacific Lung Cancer Diagnostics Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Lung Cancer Diagnostics Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Lung Cancer Diagnostics Market, 2025
5.5 Europe Lung Cancer Diagnostics Market Size Outlook by Type, 2021- 2030
5.6 Europe Lung Cancer Diagnostics Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Lung Cancer Diagnostics Market, 2025
5.8 North America Lung Cancer Diagnostics Market Size Outlook by Type, 2021- 2030
5.9 North America Lung Cancer Diagnostics Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Lung Cancer Diagnostics Market, 2025
5.11 South America Pacific Lung Cancer Diagnostics Market Size Outlook by Type, 2021- 2030
5.12 South America Lung Cancer Diagnostics Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Lung Cancer Diagnostics Market, 2025
5.14 Middle East Africa Lung Cancer Diagnostics Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Lung Cancer Diagnostics Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US Lung Cancer Diagnostics Market Size Outlook and Revenue Growth Forecasts
6.2 US Lung Cancer Diagnostics Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Lung Cancer Diagnostics Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Lung Cancer Diagnostics Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Lung Cancer Diagnostics Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Lung Cancer Diagnostics Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Lung Cancer Diagnostics Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Lung Cancer Diagnostics Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Lung Cancer Diagnostics Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Lung Cancer Diagnostics Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Lung Cancer Diagnostics Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Lung Cancer Diagnostics Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Lung Cancer Diagnostics Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Lung Cancer Diagnostics Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Lung Cancer Diagnostics Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Lung Cancer Diagnostics Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Lung Cancer Diagnostics Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Lung Cancer Diagnostics Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Lung Cancer Diagnostics Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Lung Cancer Diagnostics Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Lung Cancer Diagnostics Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Lung Cancer Diagnostics Industry Drivers and Opportunities
7. LUNG CANCER DIAGNOSTICS MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. LUNG CANCER DIAGNOSTICS COMPANY PROFILES
8.1 Profiles of Leading Lung Cancer Diagnostics Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
20/20 GENE SYSTEMS
Abbott
Amoy Diagnostics Co. Ltd
Biocartis
Biodesix
Bio-Rad Laboratories Inc
Boditech Med Inc
Danaher
DiaSorin S.p.A.
Exact Sciences UK Ltd
F. Hoffmann-La Roche Ltd.
Guardant Health Inc
Inivata Ltd.
LalPathLabs.com
LungLife AI Inc
MedGenome
Myriad Genetics Inc
Nanoentek
NanoString
NeoGenomics Laboratories
Oncocyte Corp
PerkinElmer Inc
PlexBio
QIAGEN
Quest Diagnostics Inc
Siemens Healthcare GmbH
Thermo Fisher Scientific Inc
Vela Diagnostics
Veracyte Inc
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
